Market Place
Sourcing Support
Startups raised millions to in-license drugs to China. Then the model fell apart
12 Mar 2024 //
ENDPTS
LianBio Announces Voluntarily Delisting from Nasdaq
28 Feb 2024 //
GLOBENEWSWIRE
LianBio lays off half of workforce as biotech winds down
13 Feb 2024 //
FIERCE BIOTECH
Nanobiotix Partner LianBio Assigns Its Development Rights for NBTXR3
26 Dec 2023 //
GLOBENEWSWIRE
LianBio Announces Departure of Chief Financial Officer
20 Dec 2023 //
GLOBENEWSWIRE
LianBio Announces Departure of Chief Executive Officer
19 Dec 2023 //
GLOBENEWSWIRE
LianBio`s Board of Directors Determines not to Pursue Proposal from Concentra
06 Dec 2023 //
GLOBENEWSWIRE
Concentra back with another buyout offer, this time for LianBio
02 Dec 2023 //
FIERCE BIOTECH
LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
01 Dec 2023 //
GLOBENEWSWIRE
LianBio Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03
30 Oct 2023 //
GLOBENEWSWIRE
LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib
25 Oct 2023 //
GLOBENEWSWIRE
LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten
24 Oct 2023 //
GLOBENEWSWIRE
LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten
28 Aug 2023 //
GLOBENEWSWIRE
LianBio Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
LianBio Announces First Patient Treated in Ph 1 Trial of SHP2 Inhibitor BBP-398
03 Aug 2023 //
GLOBENEWSWIRE
LianBio Partner NANOBIOTIX Enters into Agreement with Janssen for NBTXR3
18 Jul 2023 //
GLOBENEWSWIRE
LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Presentation
17 Jul 2023 //
GLOBENEWSWIRE
LianBio Announces Clinical Supply Agreement with AZ in China to Evaluate BBP-398
12 Jul 2023 //
GLOBENEWSWIRE
LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore
26 Jun 2023 //
GLOBENEWSWIRE
LianBio Announces Topline Results from Phase 2a Trial Evaluating Infigratinib
06 Jun 2023 //
GLOBENEWSWIRE
LianBio to Participate in Upcoming Investor Conferences
01 Jun 2023 //
GLOBENEWSWIRE
LianBio Announces Marketing Approval of CAMZYOS in the Macau SAR of China
11 May 2023 //
GLOBENEWSWIRE
LianBio Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
LianBio Announces Positive Topline Results from Ph 3 EXPLORER-CN Trial
26 Apr 2023 //
GLOBENEWSWIRE
LianBio Announces (NMPA) Acceptance Priority Review of NDA for Mavacamten
21 Apr 2023 //
GLOBENEWSWIRE
LianBio Promotes Pascal Qian to Chief Commercial Officer
21 Apr 2023 //
GLOBENEWSWIRE
LianBio Reports Fourth Quarter and Full Year 2022 Financial Results
27 Mar 2023 //
GLOBENEWSWIRE
Pfizer snaps up rights to RSV therapy left behind in ReViral
20 Dec 2022 //
FIERCEBIOTECH
LianBio Announces President and Chief Strategy Officer Departure
13 Dec 2022 //
GLOBENEWSWIRE
LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03
01 Nov 2022 //
GLOBENEWSWIRE
BridgeBio says it`s undeterred after Truseltiq partner withdraws application
14 Oct 2022 //
FIERCEPHARMA
Nanobiotix, LianBio randomise first subject in head/neck carcinoma trial
08 Sep 2022 //
CLINICALTRIALSARENA
LianBio completes enrollment in phase 3 EXPLORER-CN trial
12 Aug 2022 //
PHARMABIZ
LianBio Reports Q2 2022 Rusult and Provides Corporate Update
11 Aug 2022 //
GLOBENEWSWIRE
LianBio Completes Enrollment in Pivotal Phase 3 EXPLORER-CN Trial of Mavacamten
10 Aug 2022 //
GLOBENEWSWIRE
LianBio to Participate in June Investor Events
02 Jun 2022 //
GLOBENEWSWIRE
LianBio Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
LianBio Completes PI PK Study of Mavacamten in Healthy Chinese Volunteers
09 May 2022 //
GLOBENEWSWIRE
LianBio to Participate in the Bank of America Securities 2022 Conference
05 May 2022 //
GLOBENEWSWIRE
Tarsus Pharma Announces Positive Topline Data from Second Pivotal Trial of TP-03
03 May 2022 //
GLOBENEWSWIRE
U.S. FDA Approves Camzyos (mavacamten) for HCM
29 Apr 2022 //
GLOBENEWSWIRE
LianBio Announces Formation of Scientific Advisory Board
14 Apr 2022 //
GLOBENEWSWIRE
LianBio Appoints Wei Wei Chen to Board of Directors
07 Apr 2022 //
GLOBENEWSWIRE
LianBio`s Partner ReViral Enters into Acquisition Agreement with Pfizer
07 Apr 2022 //
GLOBENEWSWIRE
LianBio Reports Fourth Quarter and Full Year 2021 Financial Results
30 Mar 2022 //
GLOBENEWSWIRE
LianBio Issues Statement Regarding the HFCAA
10 Mar 2022 //
GLOBENEWSWIRE
LianBio Announces Mavacamten Granted Breakthrough Therapy Designation in China
15 Feb 2022 //
GLOBENEWSWIRE
LianBio Begins Dosing in Phase 3 Trial of Mavacamten in OHC
10 Jan 2022 //
GLOBENEWSWIRE
LianBio Announces Infigratinib Approved Under Special Named Patient Program
21 Dec 2021 //
GLOBENEWSWIRE
LianBio inks $325M IPO for pipeline with BMS, BridgeBio, Lyra
01 Nov 2021 //
FIERCEBIOTECH
LianBio Announces Launch of IPO
20 Oct 2021 //
BUSINESSWIRE
LianBio Appoints Susan Silbermann to Board of Directors
12 Oct 2021 //
BUSINESSWIRE
LianBio Appoints Michael Humphries as Chief Scientific Advisor
04 Oct 2021 //
BUSINESSWIRE
IPOs get back into gear with filings from LianBio and Xilio
04 Oct 2021 //
ENDPTS
LianBio Appoints Michael Humphries as Chief Scientific Advisor
04 Oct 2021 //
BUSINESSWIRE
IPOs get back into gear with filings from LianBio and Xilio
04 Oct 2021 //
ENDPTS
BridgeBio and LianBio Announce Patient Treated in Phase 2a Trial of Infigratinib
25 Aug 2021 //
BUSINESSWIRE
Lyra Therapeutics taps LianBio to bring sinusitis med to Asia
02 Jun 2021 //
FIERCEBIOTECH
Tarsus and LianBio Announce Strategic Partnership to Develop and TP-03
29 Mar 2021 //
GLOBENEWSWIRE
